Alira Health and Embleema Announce Partnership to Deploy Next-Generation Real-World Data Solutions for Life Sciences
28.10.2020 15:00:00 EET | Business Wire | Press release
Alira Health, a leading international healthcare and life sciences advisory firm, and Embleema, the innovative software provider for patient-driven healthcare data platforms, today announced a strategic partnership to develop next-generation real-world data solutions aimed at accelerating clinical innovation and improving patient outcomes.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201028005026/en/
"Our partnership with Embleema is a critical step in the further development of our real-world evidence capabilities, which connects clinical research, hospital care, and the patient experience,” says Gabriele Brambilla, Chief Executive Officer of Alira Health. Romain Finas, VP of Real World Evidence at Alira Health, adds, “We are excited to offer our clients new solutions for real-world data, which will empower them to better evaluate their treatments and deliver new innovations to patients more quickly.”
Robert Chu, Chief Executive Officer of Embleema added: "We are thrilled to take part in this strategic partnership with Alira Health, which is internationally recognized for the quality and the breadth of their service portfolio for life sciences. By teaming with Alira Health’s world-class consultants and experts, we will be able to better serve patients, regulators and life sciences by scaling the deployment of our technology solutions.”
Embleema’s technology solutions enable the secure exchange of real-world data and the generation of regulatory-grade evidence through the HIVE big data and bioinformatics platform currently in use by the U.S. Food and Drug Administration. Alira Health’s team of biotechnicians and data generation managers use this data to design and publish clinical studies in real-life settings and create and implement tailored data platforms for clients globally, making every data point meaningful and actionable for organizations across the healthcare ecosystem. All data is hosted in Europe.
This partnership marks an important step forward in breaking data silos with seamless end-to-end solutions that help the life sciences industry develop personalized treatments and allow hospital managers leverage their data to improve the patient experience.
About Embleema
Embleema’s unique technology platform and expertise accelerate outcomes generation and regulatory reviews for health products. Embleema was co-founded by Robert Chu, former Senior Vice-President of Global Technology at IQVIA, Dr. Vahan Simonyan, former Director of Bioinformatics R&D and lead scientist at the U.S. Food and Drug Administration and Nicolas Schmidt, former Head of Product Development, Nokia Healthcare. Embleema provides its technology to leading life sciences regulators and companies such as the U.S. FDA and Johnson & Johnson, academia such as George Washington University and New York University Langone, and patient advocacy groups such as Multiple Sclerosis Association of America and the Epilepsy Foundation.
For more information, please visit www.embleema.com.
About Alira Health
Alira Health is an international advisory firm on the frontlines of healthcare transformation. We provide a suite of integrated services designed to help healthcare and life science companies innovate and grow across their solutions lifecycle.
Alira Health was founded in 1999 and is based outside of Boston, MA, U.S. It has offices in San Francisco, CA, U.S.; Paris, France; Barcelona, Spain; Munich, Germany; Milan, Italy; and Basel and Geneva, Switzerland.
For more information, please visit www.alirahealth.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201028005026/en/
Contact information
Media:
Marlana Voerster
Director of Global Marketing
Cell: +1.617.682.6970
marlana.voerster@alirahealth.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PMC Organometallix Announces Price Increase on All Products25.4.2026 00:02:00 EEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi ® arbitral award in favor of AOP Health24.4.2026 19:52:00 EEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 17:37:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be entitled to benefits including enhanced communications and a shortened 1-2 month review time following filing of a New Drug Application (NDA), while maintaining FDA’s rigorous safety and efficacy standards. “We are honored and grateful to be selected for the CNPV which is a clear validation of both the urgent unmet need facing millions of people living with treatment resistant depression and the innovative science of COMP360,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “As the most advan
Banma Intelligence and Alipay Launch AI Cockpit Solution Powered by Alipay AI Pay, Enabling Seamless and Secure In-Car Transactions by Voice24.4.2026 17:04:00 EEST | Press release
At the 2026 Beijing International Automotive Exhibition (“Auto China 2026”), OS and AI technology company Banma Intelligence and Alipay today launched a new AI cockpit solution integrating Alipay AI Pay, enabling drivers to complete purchases by voice command directly from their vehicle. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424618328/en/ Industry-first AI Cockpit Solution with Alipay AI Pay Unveiled “In the past two years, smart cockpits have achieved rapid advances in perception and decision-making,” said Ming Cai, Banma Intelligence Chief Product Officer. “With large models onboard, vehicles can understand user intent and make recommendations. By integrating Alipay AI Pay into our AI cockpit solution, we are removing the last friction point in the in-car smart cockpit experience - drivers simply speak to pay, no phone required.” The new AI cockpit solution initially covers two high-frequency use cases: enterta
Spatial Announces the Release 2026 1.0.1: New Enhancements Across 3D InterOp, Data Prep, Meshing, and 3D Modeling SDKs24.4.2026 16:21:00 EEST | Press release
Spatial Corp., the leading software development kit provider for design, manufacturing and engineering solutions and a subsidiary of Dassault Systèmes, today announced new enhancements across several of its product lines. These updates further strengthen Spatial’s commitment to delivering high-performance solutions that optimize interoperability, data preparation, and advanced modeling workflows. Designed to improve efficiency and robustness across CAD translation, modeling, meshing, and simulation processes, the latest updates introduce expanded format support, enhanced PMI handling, and new capabilities for complex geometry processing. 3D InterOp NX Reader Enhancement for 2D Drawings The NX reader imports 2D drawings as visualization data from NX 2412 and later versions. glTF Writer Supports Draco Compression glTF export incorporates Draco compression for meshes and point-clouds to significantly reduce output file sizes. Enhanced Support for Reading Product Manufacturing Information
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom